Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Hungtington's disease

Human Molecular Genetics

Volumn 10, Issue 17, 2001, Pages 1829-1845

  Wyttenbach, Andreas ^a   Swartz, Jina ^a   Kita, Hiroko ^b   Thykjaer, Thomas ^c   Carmichael, Jenny ^a   Bradley, Jane ^d,e   Brown, Rosemary ^a   Maxwell, Michelle ^a   Schapira, Anthony ^d,e   Orntoft, Torben F ^c   Kato, Kikuya ^b   Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CASPASE; COMPLEMENTARY DNA; CYCLIC AMP; CYTOSINE; DOXYCYCLINE; FORSKOLIN; GUANINE; HUNTINGTIN; LUCIFERASE; POLYGLUTAMINE; TRINUCLEOTIDE;

ALLELE; ANIMAL CELL; ARTICLE; CELL DEATH; CELL LINE; CELL METABOLISM; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; MITOSIS; MODEL; MUTANT; NERVE CELL; NERVE FIBER GROWTH; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; REPORTER GENE; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TRINUCLEOTIDE REPEAT; UNINDEXED SEQUENCE;

ANIMALIA;

EID: 0035880474     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
2. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
3. SCA 13, a novel autosomal dominant cerebellar ataxia caused by the expanded polyglutamine in TATA-binding protein identified with IC2 antibody immunoscreening
4. An autosomal dominant disorder similar to Huntington's disease is associated with a CAG trinucleotide expansion
5. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
6. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
7. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
8. Glutamine repeats and neurodegenerative diseases: Molecular aspects
9. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease
10. Polyglutamine tract vs. protein context in SCA1 pathogenesis
11. Huntington's disease and other trinucleotide repeat disorders
12. Transcriptional activation by tetracyclines in mammalian cells
13. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3
14. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch
15. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
16. The influence of huntingtin protein size on nuclear localization and cellular toxicity
17. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
18. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
19. Formation of neuronal intracellular inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
20. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
21. Polyglutamine length-dependent interaction of hsp40 and hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity
22. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
23. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
24. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
25. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone
26. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
27. A molecular investigation of true dominance in Huntington's disease
28. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells
29. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
30. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
31. NGF induces the expression of the VGF gene through a cAMP response element
32. Molecular cloning and characterization of the promoter region of the human c-erbA α gene
33. Gene structures of rat cathepsins H and L
34. Characterisation of a CREB gain-of-function mutant with constitutive transcriptional acitivity in vivo
35. Disassembly of nuclear inclusions in the dividing cell-a novel insight into neurodegeneration
36. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases
37. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product withan expanded polyglutamine stretch
38. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
39. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
40. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
41. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin
42. CREB is cleaved by caspases during neural cell apoptosis
43. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease
44. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis
45. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients
46. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellular in situ hybridization study
47. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription
48. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
49. CREB-binding protein sequestration by expanded polyglutamine
50. p53 recruitment of CREB binding protein mediated through phosphorylated CREB: A novel pathway of tumor suppressor regulation
51. II130 are required for interactions with glutamine-rich transcription activators
52. Upregulation of cAMP response element-mediated expression during experience-dependent plasticity in adult neocortex
53. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation
54. Abnormal synpatic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation
55. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation
56. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
57. Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease
58. VGF: A novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance
59. Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism
60. Id1, Id2, and Id3 gene expression in neural cells during development
61. Isolation and characteristics of intact mitochondria
62. Anatomic and disease specificity of NADH CoQ1 reductase (complex 1) deficiency in Parkinson's disease
63. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs
64. Protein measurement with the Folin phenol reagent
65. Gene expression in the mouse cerebellum during its development
66. Correlation between gene functions and developmental expression patterns in the mouse cerebellum
67. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis
68. Functional analysis of the Huntington's disease (HD) gene promoter